Truist Securities Downgrades Terns Pharma to Hold, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 92.1%

Neg 92.1% Neu 0% Pos 0%

Truist Securities analyst Srikripa Devarakonda downgrades Terns Pharma (NASDAQ:TERN) from Buy to Hold and lowers the price target from $56 to $53.